Revised prices take effect for 1,364 anti-cancer formulations

Revised maximum retail prices have taken effect for 1,364 anti-cancer formulations after India’s drug-pricing regulator capped trade margins on 137 medicines.

The National Pharmaceutical Pricing Authority said 85 pharmaceutical companies had reported revised MRPs covering 121 of those drugs by 8 November. The government estimates annual consumer savings of ₹3,540.38 crore.

Hundreds of brands report steep reductions

Of the affected formulations reported so far, 679 brands recorded price reductions greater than 50%. The largest reported reduction was 96.45%.

The measure works through a cap on the trade margin built into the retail price rather than by setting a single uniform price for every formulation. Manufacturers and marketers must revise MRPs accordingly, while chemists and hospital pharmacies cannot charge above the new printed price.

For patients, the practical benefit depends on availability as well as the headline reduction. A lower MRP has limited value if a formulation is out of stock or replaced by a different strength or pack. Hospitals, pharmacies and distributors will therefore need to update billing systems and clear old-price inventory without overcharging.

Compliance moves to the retail counter

Consumers can verify prices through the NPPA website or Pharma Sahi Daam app. Complaints can be filed through Pharma Jan Samadhan or the regulator’s helpline.

The price action reaches a large and costly therapy category, but the 1,364 reported formulations cover 121 of the 137 drugs identified by the expert committee. Further company submissions will show how completely the order has moved through the market.

The next checkpoints are revised-price availability across hospital and retail channels, enforcement against overcharging and the realised savings compared with the government’s estimate.

Source: Department of Pharmaceuticals via PIB, 9 November 2026.